| scholarly article | Q13442814 |
| P50 | author | K. Rajender Reddy | Q69932454 |
| Mark Sulkowski | Q89653950 | ||
| P2093 | author name string | Thuluvath PJ | |
| Gao M | |||
| Nelson DR | |||
| Everson GT | |||
| Hernandez D | |||
| Lok AS | |||
| Schwartz H | |||
| Sherman D | |||
| Huang SP | |||
| Pasquinelli C | |||
| Jacobson I | |||
| Eley T | |||
| Grasela DM | |||
| Rodriguez-Torres M | |||
| Hassanein T | |||
| Lawitz E | |||
| McPhee F | |||
| Gardiner DF | |||
| Hindes R | |||
| Hinestrosa F | |||
| Symonds W | |||
| Wind-Rotolo M | |||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | daclatasvir | Q5207712 |
| sofosbuvir | Q2502747 | ||
| P304 | page(s) | 211-21 | |
| P577 | publication date | 2014-01-16 | |
| P1433 | published in | The New England Journal of Medicine | Q582728 |
| P1476 | title | Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection | |
| P478 | volume | 370 |
| Q35174428 | "Seek, test, treat and retain" for hepatitis C in the United States criminal justice system. |
| Q39077941 | "Too little, too late?" Will inhibitors of the hepatitis C virus p7 ion channel ever be used in the clinic? |
| Q36948115 | 12 Weeks of Daclatasvir in Combination With Sofosbuvir for HIV-HCV Coinfection (ALLY-2 Study): Efficacy and Safety by HIV Combination Antiretroviral Regimens |
| Q58788714 | 2017 KASL clinical practice guidelines management of hepatitis C: Treatment of chronic hepatitis C |
| Q28088762 | A 2015 roadmap for the management of hepatitis C virus infections in Asia |
| Q35915999 | A Budget Impact Analysis of Newly Available Hepatitis C Therapeutics and the Financial Burden on a State Correctional System |
| Q41011626 | A European single centre experience of management of hepatitis C virus genotype 4 infection with pegylated-interferon and ribavirin |
| Q28546535 | A Lead-In with Silibinin Prior to Triple-Therapy Translates into Favorable Treatment Outcomes in Difficult-To-Treat HIV/Hepatitis C Coinfected Patients |
| Q42345319 | A Novel Antiviral Treatment of Hepatitis C Virus Reactivation in a Breast Cancer Patient Undergoing Chemotherapy. |
| Q35962849 | A Predictive Model for Selecting Patients with HCV Genotype 3 Chronic Infection with a High Probability of Sustained Virological Response to Peginterferon Alfa-2a/Ribavirin. |
| Q36743639 | A Protease Inhibitor with Induction Therapy with Natural Interferon-β in Patients with HCV Genotype 1b Infection |
| Q53572231 | A comparison of liver disease mortality with HIV and overdose mortality among Georgia prisoners and releasees: a 2-decade cohort study of prisoners incarcerated in 1991. |
| Q38397145 | A meta-analysis platform methodology for determining the comparative effectiveness of antihepatitis C virus regimens |
| Q40784150 | A non-human hepadnaviral adjuvant for hepatitis C virus-based genetic vaccines |
| Q35449696 | A pharmacokinetic/viral kinetic model to evaluate the treatment effectiveness of danoprevir against chronic HCV. |
| Q61799789 | A prospective study of daclatasvir and sofosbuvir in chronic HCV-infected kidney transplant recipients |
| Q37187994 | A randomized, controlled study of peginterferon lambda-1a/ribavirin ± daclatasvir for hepatitis C virus genotype 2 or 3. |
| Q37279260 | A real-world intention-to-treat analysis of a decade's experience of treatment of hepatitis C with interferon-based therapies |
| Q38315788 | ABT-450: a novel agent for the treatment of CHC genotype 1: focus on treatment-experienced patients |
| Q42400012 | APASL consensus statements and recommendation on treatment of hepatitis C. |
| Q38314738 | Achieving sustained virological response: what's the impact on further hepatitis C virus-related disease? |
| Q38213321 | Advances in and the future of treatments for hepatitis C. |
| Q38556401 | Advances in hepatitis C therapies |
| Q95561254 | Advances in interferon-free hepatitis C therapy: 2014 and beyond |
| Q38215652 | Advances in newly developing therapy for chronic hepatitis C virus infection |
| Q40125281 | Adverse events associated with ribavirin in sofosbuvir-based therapies for patients with chronic hepatitis C: A community practice experience |
| Q26852595 | Aging and liver disease |
| Q26773274 | Alcoholic liver disease and hepatitis C virus infection |
| Q38581352 | Alcoholic liver disease: Clinical and translational research |
| Q38990715 | Alisporivir plus ribavirin, interferon free or in combination with pegylated interferon, for hepatitis C virus genotype 2 or 3 infection |
| Q35538245 | All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study |
| Q42202767 | All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study |
| Q59357323 | All-oral direct antiviral treatment for hepatitis C chronic infection in a real-life cohort: The role of cirrhosis and comorbidities in treatment response |
| Q24193940 | Aminoadamantanes versus other antiviral drugs for chronic hepatitis C |
| Q24194815 | Aminoadamantanes versus other antiviral drugs for chronic hepatitis C |
| Q34682186 | Amphipathic α-helices in apolipoproteins are crucial to the formation of infectious hepatitis C virus particles |
| Q38825949 | An insight into the molecular characteristics of hepatitis C virus for clinicians |
| Q40528820 | Anti-adipogenic and antiviral effects of l-carnitine on hepatitis C virus infection. |
| Q28070279 | Anti-hepatitis C virus drugs and kidney |
| Q40593359 | Anti-hepatitis C virus potency of a new autophagy inhibitor using human liver slices model |
| Q38989625 | Antiviral therapies for managing viral hepatitis in lymphoma patients. |
| Q38221090 | Antiviral therapy for chronic hepatitis C in 2014. |
| Q26748571 | Antiviral therapy for hepatitis C: Has anything changed for pregnant/lactating women? |
| Q38878814 | Antiviral treatment in patients with indolent B-cell lymphomas associated with HCV infection: a study of the Fondazione Italiana Linfomi. |
| Q42207125 | Antiviral treatment of hepatitis C. |
| Q36870118 | Antiviral treatment prioritization in HCV-infected patients with extrahepatic manifestations - An Egyptian perspective |
| Q28550601 | Assessing Hepatitis C Burden and Treatment Effectiveness through the British Columbia Hepatitis Testers Cohort (BC-HTC): Design and Characteristics of Linked and Unlinked Participants |
| Q38341993 | Assessing safety and efficacy of sofosbuvir for the treatment of hepatitis C. |
| Q91897220 | Assessing testing rates for viral hepatitis B and C by general practitioners in Flanders, Belgium: a registry-based study |
| Q35565944 | Assessing the Long-Term Impact of Treating Hepatitis C Virus (HCV)-Infected People Who Inject Drugs in the UK and the Relationship between Treatment Uptake and Efficacy on Future Infections |
| Q38980602 | Assessment of cost of innovation versus the value of health gains associated with treatment of chronic hepatitis C in the United States: The quality-adjusted cost of care |
| Q35960681 | Assessment of drug-drug interactions between daclatasvir and methadone or buprenorphine-naloxone |
| Q35776195 | Association of serum vitamin B12 levels with stage of liver fibrosis and treatment outcome in patients with chronic hepatitis C virus genotype 1 infection: a retrospective study |
| Q47553765 | Barriers to care for chronic hepatitis C in the direct-acting antiviral era: a single-centre experience |
| Q27010548 | Barriers to hepatitis C antiviral therapy in HIV/HCV co-infected patients in the United States: a review |
| Q41670432 | Baseline sensitivity of T cells to alpha-IFN correlates with sustained virological response to IFN-based triple therapy in HCV infection |
| Q38204368 | Benefit-risk assessment of new and emerging treatments for hepatitis C: focus on simeprevir and sofosbuvir |
| Q34725990 | Beyond interferon: rationale and prospects for newer treatment paradigms for chronic hepatitis C. |
| Q50903796 | Bioanalytical method validation for the simultaneous determination of ceftazidime and avibactam in rat plasma. |
| Q47547159 | Blocking Zika virus vertical transmission |
| Q35901512 | Boceprevir-Based Triple Antiviral Therapy for Chronic Hepatitis C Virus Infection in Kidney-Transplant Candidates |
| Q35854698 | Burden of hepatitis C virus disease and access to hepatitis C virus services in people who inject drugs in India: a cross-sectional study |
| Q34775524 | CIHR Canadian HIV Trials Network Co-Infection and Concurrent Diseases Core: Updated Canadian guidelines for the treatment of hepatitis C infection in HIV-hepatitis C coinfected adults |
| Q37100669 | CIHR Canadian HIV Trials Network Coinfection and Concurrent Diseases Core Research Group: 2016 Updated Canadian HIV/Hepatitis C Adult Guidelines for Management and Treatment |
| Q59349176 | Can Broadly Neutralizing Monoclonal Antibodies Lead to a Hepatitis C Virus Vaccine? |
| Q41996616 | Can we go for a shorter treatment course in chronic hepatitis C? More inspiring cases |
| Q38675565 | Cell transplantation as a non-invasive strategy for treating liver fibrosis |
| Q27011203 | Changing the face of hepatitis C management - the design and development of sofosbuvir |
| Q40548267 | Characterization of NS5A polymorphisms and their impact on response rates in patients with HCV genotype 2 treated with daclatasvir-based regimens |
| Q38637199 | Characterization of Naturally Occurring NS5A and NS5B Polymorphisms in Patients Infected with HCV Genotype 3a Treated with Direct-Acting Antiviral Agents |
| Q42201573 | Characterization of hepatitis C virus intergenotypic recombinant strains and associated virological response to sofosbuvir/ribavirin |
| Q40646372 | Chronic Hepatitis C - Therapeutic Options in 2016 |
| Q87924400 | Chronic Hepatitis C Infection in Children |
| Q36981033 | Chronic Hepatitis C Virus Infection: A Review of Current Direct-Acting Antiviral Treatment Strategies |
| Q33421570 | Chronic hepatitis C - what do the new drugs offer and who should get them first? |
| Q38198992 | Chronic hepatitis C in the aged: much ado about nothing or nothing to do? |
| Q26775011 | Chronic hepatitis C: This and the new era of treatment |
| Q28080225 | Clinical Laboratory Testing in the Era of Directly Acting Antiviral Therapies for Hepatitis C |
| Q59353401 | Clinical and epidemiological characteristics of hepatitis C virus-infected people who inject drugs: a Greek descriptive analysis |
| Q34736194 | Clinical practice guideline for the management of chronic kidney disease in patients infected with HIV: 2014 update by the HIV Medicine Association of the Infectious Diseases Society of America |
| Q38544516 | Comparative efficacy and safety of daclatasvir/asunaprevir versus IFN-based regimens in genotype 1b hepatitis C virus infection. |
| Q42109722 | Comparison of daclatasvir resistance barriers on NS5A from hepatitis C virus genotypes 1 to 6: implications for cross-genotype activity. |
| Q28075544 | Concise review: Interferon-free treatment of hepatitis C virus-associated cirrhosis and liver graft infection |
| Q92625996 | Consensus on management of hepatitis C virus infection in resource-limited Ukraine and Commonwealth of Independent States regions |
| Q37265764 | Consequences of inaccurate hepatitis C virus genotyping on the costs of prescription of direct antiviral agents in an Italian district |
| Q35759025 | Consideration of Viral Resistance for Optimization of Direct Antiviral Therapy of Hepatitis C Virus Genotype 1-Infected Patients |
| Q33629561 | Cost Effectiveness and Cost Containment in the Era of Interferon-Free Therapies to Treat Hepatitis C Virus Genotype 1 |
| Q97679007 | Cost and Effectiveness of the Treatment of Chronic Hepatitis C in Brazil: Real-World Data |
| Q33734454 | Cost per care of the first year of direct antiviral agents in the Liguria Region: a multicenter analysis |
| Q46581705 | Cost-Effectiveness Analysis of New HCV Treatments in Egyptian Cirrhotic and Non-Cirrhotic Patients: A Societal Perspective |
| Q36155257 | Cost-Effectiveness of Hepatitis C Treatment for People Who Inject Drugs and the Impact of the Type of Epidemic; Extrapolating from Amsterdam, the Netherlands |
| Q36238515 | Cost-Effectiveness of Treating Hepatitis C with Sofosbuvir/Ledipasvir in Germany |
| Q54984374 | Cost-Effectiveness of Treatments for Genotype 1 Hepatitis C Virus Infection in non-VA and VA Populations. |
| Q40584662 | Cost-effectiveness analysis of therapeutic options for chronic hepatitis C genotype 3 infected patients |
| Q57071808 | Cost-effectiveness analysis of treatment timing considering the future entry of lower-cost generics for hepatitis C |
| Q40688211 | Cost-effectiveness and budget impact of interferon-free direct-acting antiviral-based regimens for hepatitis C treatment: the French case |
| Q38295834 | Cure of HCV related liver disease |
| Q38295798 | Current and future HCV therapy: do we still need other anti-HCV drugs? |
| Q39151677 | Current therapy for chronic hepatitis C: The role of direct-acting antivirals |
| Q38707895 | Current treatment options for hepatitis C patients co-infected with HIV. |
| Q26769624 | Daclatasvir |
| Q40949225 | Daclatasvir + asunaprevir + beclabuvir ± ribavirin for chronic HCV genotype 1-infected treatment-naive patients |
| Q42200398 | Daclatasvir + asunaprevir: first global approval |
| Q39007700 | Daclatasvir combined with sofosbuvir or simeprevir in liver transplant recipients with severe recurrent hepatitis C infection |
| Q38859473 | Daclatasvir for the Treatment of Chronic Hepatitis C: A Critique of the Clinical and Economic Evidence |
| Q38628237 | Daclatasvir for the treatment of chronic hepatitis C. |
| Q38216586 | Daclatasvir for the treatment of hepatitis C virus infection. |
| Q64083658 | Daclatasvir plus Sofosbuvir with or without ribavirin in patients with chronic Hepatitis C genotype 3a in Pakistani population - A real world experience |
| Q35044909 | Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection |
| Q42202640 | Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study |
| Q36724391 | Daclatasvir vs telaprevir plus peginterferon alfa/ribavirin for hepatitis C virus genotype 1 |
| Q37349067 | Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence |
| Q28077287 | Daclatasvir-based Treatment Regimens for Hepatitis C Virus Infection: A Systematic Review and Meta-Analysis |
| Q26750628 | Daclatasvir-sofosbuvir combination therapy with or without ribavirin for hepatitis C virus infection: from the clinical trials to real life |
| Q40638362 | Daclatasvir/peginterferon lambda-1a/ribavirin in patients with chronic HCV infection and haemophilia who are treatment naïve or prior relapsers to peginterferon alfa-2a/ribavirin |
| Q38612647 | Daclatasvir: A NS5A Replication Complex Inhibitor for Hepatitis C Infection |
| Q30392100 | Daclatasvir: A Review in Chronic Hepatitis C. |
| Q38365658 | Daclatasvir: a review of its use in adult patients with chronic hepatitis C virus infection |
| Q42192444 | Daclatasvir: a team player rather than a prima donna in the treatment of hepatitis C. |
| Q38665683 | Defining the possibilities: is short duration treatment of chronic hepatitis C genotype 1 with sofosbuvir-containing regimens likely to be as effective as current regimens? |
| Q59355776 | Design and Development of Modified mRNA Encoding Core Antigen of Hepatitis C Virus: a Possible Application in Vaccine Production |
| Q38515906 | Development of antiviral drugs for the treatment of hepatitis C at an accelerating pace |
| Q44337654 | Direct Observed Therapy of Chronic Hepatitis C With Interferon-Free All-Oral Regimens at a Low-Threshold Drug Treatment Facility-a New Concept for Treatment of Patients With Borderline Compliance Receiving Opioid Substitution Therapy |
| Q40333567 | Direct antiviral agent treatment of decompensated hepatitis C virus-induced liver cirrhosis |
| Q35905985 | Direct-acting Antiviral Agents for the Treatment of Chronic Hepatitis C Virus Infection |
| Q40107697 | Direct-acting antiviral agent efficacy and safety in renal transplant recipients with chronic hepatitis C virus infection: A PRISMA-compliant study |
| Q38826176 | Direct-acting antiviral agents for hepatitis C: structural and mechanistic insights |
| Q59360860 | Direct-acting antiviral agents in patients with hepatitis C genotype 1-4 infections in a tertiary hospital |
| Q41201956 | Direct-acting antiviral treatment of chronic hepatitis C infection |
| Q57389418 | Direct-acting antivirals for chronic hepatitis C |
| Q34557595 | Direct-acting antivirals for chronic hepatitis C. |
| Q38204468 | Directly acting antivirals (DAAs) for the treatment of chronic hepatitis C virus infection in liver transplant patients: "a flood of opportunity". |
| Q40118647 | Directly observed therapy of sofosbuvir/ribavirin +/- peginterferon with minimal monitoring for the treatment of chronic hepatitis C in people with a history of drug use in Chennai, India (C-DOT). |
| Q37018340 | Disparities in Absolute Denial of Modern Hepatitis C Therapy by Type of Insurance |
| Q30276614 | Distinct Roles for Intracellular and Extracellular Lipids in Hepatitis C Virus Infection |
| Q39010715 | Do disparities between populations in randomized controlled trials and the real world lead to differences in outcomes? |
| Q28550311 | Drug Pricing Evolution in Hepatitis C |
| Q40143109 | Drug interactions in HIV-infected patients treated for hepatitis C. |
| Q37735902 | Drug therapies for chronic hepatitis C infection: a cost-effectiveness analysis |
| Q40506459 | Drug-Induced Lung Injury in a Liver Transplant Patient Treated With Sofosbuvir. |
| Q38554604 | Dual antiviral therapy for HIV and hepatitis C - drug interactions and side effects. |
| Q38631256 | Dual daclatasvir and sofosbuvir for treatment of genotype 3 chronic hepatitis C virus infection |
| Q37641605 | Dynamics of PBMC gene expression in hepatitis C virus genotype 1-infected patients during combined peginterferon/ribavirin therapy |
| Q38846558 | Early Treatment in HCV: Is it a Cost-Utility Option from the Italian Perspective? |
| Q64068380 | Economic evaluation of the hepatitis C elimination strategy in Greece in the era of affordable direct-acting antivirals |
| Q50280201 | Editorial: can we afford the new direct-acting anti-virals for treatment of genotype 1 hepatitis C? Authors' reply |
| Q38909432 | Effect of Chronic Hepatitis C Virus Treatment by Combination Therapy on Cardiovascular System |
| Q40279496 | Effect of Gender on the Response to Hepatitis C Treatment in an Inner-City Population |
| Q36255875 | Effect of Peginterferon or Ribavirin Dosing on Efficacy of Therapy With Telaprevir in Treatment-Experienced Patients With Chronic Hepatitis C and Advanced Liver Fibrosis: A Multicenter Cohort Study. |
| Q53684076 | Effect of Sofosbuvir Plus Daclatasvir in Hepatitis C Virus Genotype-4 Patients: Promising Effect on Liver Fibrosis. |
| Q38946893 | Effectiveness and safety of daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: Systematic review and meta-analysis |
| Q39015799 | Efficacy and Safety of Daclatasvir in Hepatitis C: An Overview |
| Q40297644 | Efficacy and Safety of Sofosbuvir-Based Antiviral Therapy to Treat Hepatitis C Virus Infection After Kidney Transplantation. |
| Q38375284 | Efficacy and safety of 3-week response-guided triple direct-acting antiviral therapy for chronic hepatitis C infection: a phase 2, open-label, proof-of-concept study |
| Q40328514 | Efficacy and safety of daclatasvir plus pegylated-interferon alfa 2a and ribavirin in previously untreated HCV subjects coinfected with HIV and HCV genotype-1: a Phase III, open-label study |
| Q40080544 | Efficacy and safety of ledipasvir/sofosbuvir with ribavirin in chronic hepatitis C patients who failed daclatasvir/asunaprevir therapy: pilot study |
| Q41608541 | Efficacy and safety of sofosbuvir and daclatasvir in treatment of kidney transplantation recipients with hepatitis C virus infection |
| Q54213480 | Efficacy and safety of sofosbuvir plus daclatasvir with or without ribavirin: large real-life results of patients with chronic hepatitis C genotype 4. |
| Q47098950 | Efficacy and safety of sofosbuvir-based therapies in patients with advanced liver disease in a real-life cohort |
| Q90156215 | Efficacy and safety of the new antiviral agents for the treatment of hepatitis C virus infection in Egyptian renal transplant recipients |
| Q38837174 | Efficacy of Interferon-Free Therapies for Chronic Hepatitis C: A Systematic Review of All Randomized Clinical Trials. |
| Q26771458 | Efficacy of Second Generation Direct-Acting Antiviral Agents for Treatment Naïve Hepatitis C Genotype 1: A Systematic Review and Network Meta-Analysis |
| Q38233602 | Efficacy of daclatasvir in hepatitis C virus |
| Q26741123 | Elbasvir/Grazoprevir: A Review of the Latest Agent in the Fight against Hepatitis C |
| Q26853642 | Emerging therapies for hepatitis C |
| Q38233245 | Enhanced antiviral treatment efficacy and uptake in preventing the rising burden of hepatitis C-related liver disease and costs in Australia |
| Q28085718 | Enhancing our understanding of current therapies for hepatitis C virus (HCV) |
| Q90955086 | Epidemiología, consumo de recursos y costos del manejo médico de la Hepatitis C en Argentina, Colombia, Uruguay y Venezuela |
| Q36242517 | Estimating the Cost-Effectiveness of One-Time Screening and Treatment for Hepatitis C in Korea. |
| Q35031753 | Estimating the clinical and economic benefit associated with incremental improvements in sustained virologic response in chronic hepatitis C |
| Q40902793 | Evaluating Andrographolide as a Potent Inhibitor of NS3-4A Protease and Its Drug-Resistant Mutants Using In Silico Approaches |
| Q55717379 | Evolution of patients' socio-behavioral characteristics in the context of DAA: Results from the French ANRS CO13 HEPAVIH cohort of HIV-HCV co-infected patients. |
| Q57490314 | Expert opinion on the management of hepatitis C infection in Kuwait |
| Q39453035 | Fibrosing Cholestatic Hepatitis C After Liver Transplantation: Therapeutic Options Before and After Introduction of Direct-Acting Antivirals: Our Experience and Literature Review. |
| Q26822400 | Finally sofosbuvir: an oral anti-HCV drug with wide performance capability |
| Q38256237 | Finding a cure for human immunodeficiency virus-1 infection |
| Q35164782 | First-generation protease inhibitor-triple therapy: SVR 24, safety, and predictors of response in a large single center cohort |
| Q38353529 | Fixed-dose combination of sofosbuvir and ledipasvir for the treatment of chronic hepatitis C genotype 1. |
| Q38888859 | Frequency of Natural Resistance within NS5a Replication Complex Domain in Hepatitis C Genotypes 1a, 1b: Possible Implication of Subtype-Specific Resistance Selection in Multiple Direct Acting Antivirals Drugs Combination Treatment. |
| Q36865009 | Functional differences in hepatitis C virus nonstructural (NS) 3/4A- and 5A-specific T cell responses |
| Q30235178 | Future of liver disease in the era of direct acting antivirals for the treatment of hepatitis C |
| Q46445455 | Generic daclatasvir plus sofosbuvir, with or without ribavirin, in treatment of chronic hepatitis C: real-world results from 18 378 patients in Egypt. |
| Q57945693 | Generic sofosbuvir-based interferon-free direct acting antiviral agents for patients with chronic hepatitis C virus infection: a real-world multicenter observational study |
| Q37635067 | Genetic variants in interferon-λ 4 influences HCV clearance in Chinese Han population |
| Q91656334 | Genotype 3: Treat now or wait for something better? |
| Q48100807 | Germline genetic variants with implications for disease risk and therapeutic outcomes |
| Q34431175 | Global distribution and prevalence of hepatitis C virus genotypes |
| Q30245058 | Global epidemiology of hepatitis C virus infection: An up-date of the distribution and circulation of hepatitis C virus genotypes |
| Q36461735 | Global epidemiology of hepatocellular carcinoma: an emphasis on demographic and regional variability |
| Q38757717 | Grazoprevir + elbasvir for the treatment of hepatitis C virus infection |
| Q54210704 | Grazoprevir/elbasvir for the treatment of adults with chronic hepatitis C: a short review on the clinical evidence and place in therapy. |
| Q58737372 | HA1077 displays synergistic activity with daclatasvir against hepatitis C virus and suppresses the emergence of NS5A resistance-associated substitutions in mice |
| Q31012317 | HCV Council--critical appraisal of data: recommendations for clinical practice in a rapidly evolving therapeutic landscape |
| Q57168365 | HCV NS3/4A Protease Inhibitors and the Road to Effective Direct-Acting Antiviral Therapies |
| Q41407052 | HCV NS5A resistance-associated variants in a group of real-world Japanese patients chronically infected with HCV genotype 1b. |
| Q44998162 | HCV core antigen is an alternative marker to HCV RNA for evaluating active HCV infection: implications for improved diagnostic option in an era of affordable DAAs |
| Q37098242 | HCV cure for everyone or which challenges remain? |
| Q58775051 | HCV elimination among people who inject drugs. Modelling pre- and post-WHO elimination era |
| Q38372939 | HCV management in resource-constrained countries. |
| Q35535844 | HCV treatment rates and sustained viral response among people who inject drugs in seven UK sites: real world results and modelling of treatment impact. |
| Q50282700 | HCV-associated cryoglobulinemic vasculitis: triple/dual antiviral treatment and/or rituximab? Reply to the comment by Ignatova et al. |
| Q41172135 | HIV Coinfected Have Similar SVR Rates as HCV Monoinfected With DAAs: It's Time to End Segregation and Integrate HIV Patients Into HCV Trials |
| Q26996736 | HIV and hepatitis C virus infection in the United States: whom and how to test |
| Q35865208 | HIV treatment and care among Italian inmates: a one-month point survey |
| Q59356597 | Has Access to HCV Therapy Changed for Patients with Mental Health or Substance Use Disorders in the DAA Period? |
| Q40732010 | Health Beliefs and Co-morbidities Associated with Appointment-Keeping Behavior Among HCV and HIV/HCV Patients |
| Q90450274 | Heart Transplantation From Hepatitis C-Positive Donors in the Era of Direct Acting Antiviral Therapy: A Comprehensive Literature Review |
| Q36649138 | Hepatitis B and C in pregnancy: a review and recommendations for care. |
| Q28084654 | Hepatitis C |
| Q90834044 | Hepatitis C |
| Q26781743 | Hepatitis C Associated B-cell Non-Hodgkin Lymphoma: Clinical Features and the Role of Antiviral Therapy |
| Q34332546 | Hepatitis C NS5A protein: two drug targets within the same protein with different mechanisms of resistance |
| Q38961563 | Hepatitis C Treatment and Barriers to Eradication |
| Q50881536 | Hepatitis C Treatment in 2016: Reasons to Be an OPTIMIST. |
| Q33576161 | Hepatitis C Virus Treatment in HIV-Coinfected Patients: No Longer Different From Monoinfection Treatment |
| Q26801828 | Hepatitis C Virus Treatment: Is It Possible To Cure All Hepatitis C Virus Patients? |
| Q40808459 | Hepatitis C Virus universal screening versus risk based selective screening during pregnancy |
| Q45325225 | Hepatitis C and Human Immunodeficiency Virus Co-Infection in the Era of Direct-Acting Antiviral Agents: No Longer A Difficult to Treat Population |
| Q38800572 | Hepatitis C disease transmission and treatment uptake: impact on the cost-effectiveness of new direct-acting antiviral therapies |
| Q34439125 | Hepatitis C drugs: the end of the pegylated interferon era and the emergence of all-oral interferon-free antiviral regimens: a concise review |
| Q30244065 | Hepatitis C genotype 3 disease. |
| Q26775815 | Hepatitis C genotype 4: The past, present, and future |
| Q38215318 | Hepatitis C in HIV-infected patients: impact of direct-acting antivirals |
| Q33585021 | Hepatitis C in a New Era: A Review of Current Therapies |
| Q40989823 | Hepatitis C treatment as prevention of viral transmission and liver-related morbidity in persons who inject drugs. |
| Q30378509 | Hepatitis C treatment: where are we now? |
| Q28552909 | Hepatitis C virus Broadly Neutralizing Monoclonal Antibodies Isolated 25 Years after Spontaneous Clearance |
| Q40109851 | Hepatitis C virus NS5A region mutation in chronic hepatitis C genotype 1 patients who are non-responders to two or more treatments and its relationship with response to a new treatment |
| Q28546101 | Hepatitis C virus RNA replication depends on specific cis- and trans-acting activities of viral nonstructural proteins |
| Q57295205 | Hepatitis C virus cell culture models: an encomium on basic research paving the road to therapy development |
| Q38456906 | Hepatitis C virus genetic variability and evolution. |
| Q24658456 | Hepatitis C virus genotype 3: Meta-analysis on sustained virologic response rates with currently available treatment options |
| Q38249236 | Hepatitis C virus genotype 3: a genotype that is not 'easy-to-treat'. |
| Q56896011 | Hepatitis C virus infection |
| Q38265395 | Hepatitis C virus infection treatment: An era of game changer direct acting antivirals and novel treatment strategies |
| Q38887954 | Hepatitis C virus resistance to the new direct-acting antivirals |
| Q38374284 | Hepatitis C virus therapeutic development: in pursuit of "perfectovir". |
| Q35501190 | Hepatitis C virus: Is it time to say goodbye yet? Perspectives and challenges for the next decade |
| Q27468916 | Hepatitis C virus: Promising discoveries and new treatments |
| Q38945754 | Hepatitis C virus: life cycle in cells, infection and host response, and analysis of molecular markers influencing the outcome of infection and response to therapy. |
| Q38812892 | Hepatitis C-A clinical review |
| Q26798465 | Hepatitis C: Treatment of difficult to treat patients |
| Q42212155 | Hepatitis C: Treatment triumphs |
| Q26765433 | Hepatitis Vaccines |
| Q91605669 | Hepatocellular carcinoma occurs frequently and early after treatment in HCV genotype 3 infected persons treated with DAA regimens |
| Q35907984 | High Sustained Virologic Response to Daclatasvir Plus Asunaprevir in Elderly and Cirrhotic Patients with Hepatitis C Virus Genotype 1b Without Baseline NS5A Polymorphisms |
| Q40829360 | High antiviral activity of NS5A inhibitor ABT-530 with paritaprevir/ritonavir and ribavirin against hepatitis C virus genotype 3 infection |
| Q40056569 | High-Risk Geographic Mobility Patterns among Young Urban and Suburban Persons who Inject Drugs and their Injection Network Members |
| Q36997093 | Highlights of the Fourth Canadian Symposium on Hepatitis C: Moving towards a National Action Plan |
| Q33745372 | Immunological Predictors of Nonresponse to Directly Acting Antiviral Therapy in Patients With Chronic Hepatitis C and Decompensated Cirrhosis |
| Q38893104 | Impact of HCV genotype on treatment regimens and drug resistance: a snapshot in time |
| Q40508435 | Impact of IFNL4 rs12979860 and rs8099917 polymorphisms on response to Peg-Interferon-α and Ribavirin in patients with congenital bleeding disorder and chronic hepatitis C. |
| Q41065311 | Improvement of liver function parameters in advanced HCV-associated liver cirrhosis by IFN-free antiviral therapies |
| Q41595435 | In Vitro Assessment of Re-treatment Options for Patients with Hepatitis C Virus Genotype 1b Infection Resistant to Daclatasvir Plus Asunaprevir |
| Q40280432 | Increased mortality among persons with chronic hepatitis C with moderate or severe liver disease: a cohort study |
| Q30355190 | Indian National Association for Study of the Liver (INASL) Guidance for Antiviral Therapy Against HCV Infection: Update 2016. |
| Q33706737 | Inducible protein-10 as a predictive marker of antiviral hepatitis C treatment: A systematic review |
| Q91656382 | Integrating daclatasvir into hepatitis c therapy |
| Q28080876 | Interferon therapy in hepatitis C leading to chronic type 1 diabetes |
| Q26781331 | Interferon-Free Hepatitis C Treatment before and after Liver Transplantation: The Role of HCV Drug Resistance |
| Q38741305 | Interferon-Free Therapy in Elderly Patients With Advanced Liver Disease |
| Q36837502 | Interferon-Free Treatment of Hepatitis C Virus in HIV/Hepatitis C Virus-Coinfected Subjects Results in Increased Serum Low-Density Lipoprotein Concentration |
| Q42210289 | Interferon-based treatment for patients with mycosis fungoides and hepatitis C virus infection: a case series. |
| Q38416448 | Interferon-free antiviral treatment of chronic hepatitis C in the transplant setting |
| Q28087400 | Interferon-free combination therapies for the treatment of hepatitis C: current insights |
| Q41582122 | Interferon-free regimens for chronic hepatitis C overcome the effects of portal hypertension on virological responses |
| Q38530211 | Interferon-free, direct-acting antiviral therapy for chronic hepatitis C. |
| Q90612954 | International trends in hepatocellular carcinoma incidence, 1978-2012 |
| Q38842781 | Is elimination of HCV possible in a country with low diagnostic rate and moderate HCV prevalence?: The case of Greece. |
| Q40458975 | Is stronger better in curing hepatitis C virus infection? |
| Q38556915 | Is the 25-year hepatitis C marathon coming to an end to declare victory? |
| Q26752471 | KASL clinical practice guidelines: management of hepatitis C |
| Q38236179 | Latest pharmacotherapy options for treating hepatitis C in HIV-infected patients. |
| Q40189279 | Ledipasvir-Sofosbuvir Plus Ribavirin in Treatment-Naive Patients With Hepatitis C Virus Genotype 3 Infection: An Open-Label Study |
| Q40357542 | Ledipasvir-sofosbuvir and sofosbuvir plus ribavirin in patients with chronic hepatitis C and bleeding disorders |
| Q41429836 | Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS). |
| Q57063280 | Long-term changes in liver elasticity in hepatitis C virus-infected patients with sustained virologic response after treatment with direct-acting antivirals |
| Q41931578 | Long-term follow-up of clinical trial patients treated for chronic HCV infection with daclatasvir-based regimens |
| Q33390630 | Long-term functional duration of immune responses to HCV NS3/4A induced by DNA vaccination |
| Q41465071 | MEDICINE. Global control of hepatitis C virus |
| Q38432047 | Management of HCV in cirrhosis-a rapidly evolving landscape |
| Q26740320 | Management of HCV-Associated Liver Cirrhosis |
| Q26781741 | Management of Hepatitis C Post-liver Transplantation: a Comprehensive Review |
| Q37312151 | Management of hepatitis C genotype 4 in the directly acting antivirals era. |
| Q34932338 | Management of hepatitis C in patients with chronic kidney disease. |
| Q38702156 | Management of hepatitis C patients with decompensated liver disease. |
| Q30234831 | Management of hepatitis C virus infection in the Asia-Pacific region: an update |
| Q41923026 | Manipulation of both virus- and cell-specific factors is required for robust transient replication of a hepatitis C virus genotype 3a sub-genomic replicon. |
| Q26773321 | Mechanisms of Hepatitis C Viral Resistance to Direct Acting Antivirals |
| Q37015686 | Men with severe hemophilia in the United States: birth cohort analysis of a large national database |
| Q40715802 | Methods to Evaluate Novel Hepatitis C Virus Vaccines |
| Q34452419 | Minimum target prices for production of direct-acting antivirals and associated diagnostics to combat hepatitis C virus |
| Q36889376 | Modelling the interaction between danoprevir and mericitabine in the treatment of chronic HCV infection. |
| Q37089469 | Morbidity and Mortality Among Community-Based People Who Inject Drugs With a High Hepatitis C and Human Immunodeficiency Virus Burden in Chennai, India |
| Q41147723 | Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 in patients with cirrhosis. |
| Q38875280 | New Direct-Acting Antiviral Therapies for Treatment of Chronic Hepatitis C Virus Infection |
| Q33560181 | New Therapies for Hepatitis C Virus Infection |
| Q91599092 | New Treatments for Hepatitis C |
| Q26773271 | New approaches in the treatment of hepatitis C |
| Q50283732 | New direct-acting antiviral agents for the treatment of chronic hepatitis C in 2014 |
| Q38664453 | New direct-acting antivirals in hepatitis C therapy: a review of sofosbuvir, ledipasvir, daclatasvir, simeprevir, paritaprevir, ombitasvir and dasabuvir |
| Q26800050 | New era for management of chronic hepatitis C virus using direct antiviral agents: A review |
| Q39016874 | New era in treatment options of chronic hepatitis C: focus on safety of new direct-acting antivirals (DAAs). |
| Q41622257 | New kids on the block--step by step to an ideal HCV therapy |
| Q42947767 | New nucleotide polymerase inhibitors to rapidly permit hematopoietic stem cell donation from a positive HCV-RNA donor |
| Q26795407 | New treatment strategies for hepatitis C infection |
| Q45324359 | Newer direct-acting antivirals for hepatitis C virus infection: Perspectives for India |
| Q26747561 | Next Steps Toward Eradication of Hepatitis C in the Era of Direct Acting Antivirals |
| Q35873113 | Next-Generation Sequencing Reveals Frequent Opportunities for Exposure to Hepatitis C Virus in Ghana |
| Q40151847 | Noninvasive serum models to predict significant liver related events in chronic hepatitis C. |
| Q60960505 | Novel adeno‑associated virus‑based genetic vaccines encoding hepatitis C virus E2 glycoprotein elicit humoral immune responses in mice |
| Q39985325 | Occurrence and Recurrence of Hepatocellular Carcinoma Were Not Rare Events during Phlebotomy in Older Hepatitis C Virus-Infected Patients |
| Q38262922 | Ombitasvir (ABT-267), a novel NS5A inhibitor for the treatment of hepatitis C. |
| Q41514826 | On computer-intensive simulation and estimation methods for rare-event analysis in epidemic models. |
| Q91656878 | Opciones terapéuticas para los pacientes con hepatitis C crónica y fracaso terapéutico previo |
| Q42220134 | Opening Fronts in HIV Vaccine Development: Targeting reservoirs to clear and cure |
| Q38295826 | Optimal IFN-free therapy in treatment-naïve patients with HCV genotype 1 infection |
| Q38295831 | Optimal interferon-free therapy in treatment-experienced chronic hepatitis C patients |
| Q38295814 | Optimal therapy in genotype 4 chronic hepatitis C: finally cured? |
| Q38295810 | Optimal therapy of genotype-2 chronic hepatitis C: what's new? |
| Q50532119 | Optimization of direct anti-viral agent treatment schedule: Focus on HCV genotype 3. |
| Q38249065 | Optimizing triple therapy and IFN/RBV-free regimens for hepatitis C virus infection |
| Q38893244 | Oral Direct-Acting Agent Therapy for Hepatitis C Virus Infection: A Systematic Review |
| Q54239807 | Outcomes and predictors of treatment response with sofosbuvir plus daclatasvir with or without ribavirin in Egyptian patients with genotype 4 hepatitis C virus infection. |
| Q33821728 | Outcomes from a large 10 year hepatitis C treatment programme in people who inject drugs: No effect of recent or former injecting drug use on treatment adherence or therapeutic response |
| Q38470584 | Outcomes, costs and cost-effectiveness of treating hepatitis C with direct acting antivirals |
| Q38876302 | Patient engagement and study design of PROP UP: A multi-site patient-centered prospective observational study of patients undergoing hepatitis C treatment |
| Q40374154 | Patients with Haemoglobinopathies and Chronic Hepatitis C: A Real Difficult to Treat Population in 2016? |
| Q36163864 | Peginterferon alfa-2a plus Weight-Based or Flat-Dose Ribavirin for Treatment-Naïve Hepatitis C Virus Genotype 2 Rapid Responders: A Randomized Trial |
| Q42223532 | Peginterferon alfa-2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 2 receiving haemodialysis: a randomised trial |
| Q35803105 | Peginterferon plus weight-based ribavirin for treatment-naïve hepatitis C virus genotype 2 patients not achieving rapid virologic response: a randomized trial |
| Q35412591 | Performance of two HCV RNA assays during protease inhibitor-based triple therapy in patients with advanced liver fibrosis and cirrhosis. |
| Q38927205 | Perspectives on HCV: Current Therapeutic Regimens and Drug-Drug Interactions |
| Q38724091 | Pharmacodynamics and pharmacokinetics of elbasvir and grazoprevir in the treatment of hepatitis C. |
| Q24186846 | Pharmacological treatments for chronic hepatitis C liver disease: a network meta-analysis |
| Q41564973 | Plasma apolipoprotein H limits HCV replication and associates with response to NS3 protease inhibitors-based therapy |
| Q37373261 | Polymorphisms and resistance mutations of hepatitis C virus on sequences in the European hepatitis C virus database. |
| Q38995225 | Polymorphisms at IL28B gene as predictors of viral relapse in genotype 4 Egyptian hepatitis C patients. |
| Q28550423 | Potential for Drug-Drug Interactions between Antiretrovirals and HCV Direct Acting Antivirals in a Large Cohort of HIV/HCV Coinfected Patients |
| Q38902281 | Potential market size and impact of hepatitis C treatment in low- and middle-income countries. |
| Q40305694 | Predicting the development of liver cirrhosis by simple modelling in patients with chronic hepatitis C. |
| Q35790397 | Predictive factors associated with hepatitis C antiviral therapy response |
| Q34506224 | Predictive value of interferon-lambda gene polymorphisms for treatment response in chronic hepatitis C. |
| Q47562294 | Predictors of Longitudinal Trajectories of Alcohol Consumption in People with HIV. |
| Q35942041 | Predictors of Pegylated Interferon Alpha and Ribavirin Efficacy and Long-Term Assessment of Relapse in Patients With Chronic Hepatitis C: A One-Center Experience From China |
| Q40343824 | Predictors of treatment efficacy and ALT non-normalization with sofosbuvir/ribavirin therapy for patients with hepatitis C virus genotype 2. |
| Q59462696 | Predisposing, enabling, and need factors associated with utilization of HCV testing services among PWID in two settings in India |
| Q36506480 | Prevalence of HCV NS3 pre-treatment resistance associated amino acid variants within a Scottish cohort |
| Q64928335 | Prevalence of and risk factors for hepatitis C virus antibody among people who inject drugs in Cambodia: a national biological and behavioral survey. |
| Q39020651 | Prevalence of polymorphisms with significant resistance to NS5A inhibitors in treatment-naive patients with hepatitis C virus genotypes 1a and 3a in Sweden |
| Q38826624 | Prevention and management of treatment failure to new oral hepatitis C drugs. |
| Q27005712 | Prodrugs of phosphonates and phosphates: crossing the membrane barrier |
| Q41016420 | Protease inhibitors partially overcome the interferon nonresponse phenotype in patients with chronic hepatitis C. |
| Q38264060 | Provision of clinical pharmacist services for individuals with chronic hepatitis C viral infection: Joint Opinion of the GI/Liver/Nutrition and Infectious Diseases Practice and Research Networks of the American College of Clinical Pharmacy |
| Q26798477 | Psychiatric and substance use disorders co-morbidities and hepatitis C: Diagnostic and treatment implications |
| Q42213830 | QUEST for a cure for hepatitis C virus: the end is in sight |
| Q56957250 | Quasispecies and Drug Resistance |
| Q39754109 | Race/ethnicity-specific disparities in cancer incidence, burden of disease, and overall survival among patients with hepatocellular carcinoma in the United States. |
| Q36014286 | Randomized Trial Evaluating the Impact of Ribavirin Mono-Therapy and Double Dosing on Viral Kinetics, Ribavirin Pharmacokinetics and Anemia in Hepatitis C Virus Genotype 1 Infection |
| Q41064382 | Randomized comparison of daclatasvir + asunaprevir versus telaprevir + peginterferon/ribavirin in Japanese hepatitis C virus patients |
| Q92757591 | Rapid decrease in titer and breadth of neutralizing anti-HCV antibodies in HIV/HCV-coinfected patients who achieved SVR |
| Q41521289 | Real-life prevalence of resistance-associated variants against non-structural protein 5A inhibitors and efficiency of Daclatasvir + Asunaprevir therapy in Korean patients with genotype 1b hepatitis C |
| Q55514100 | Real-world Efficacy of Direct-Acting Antiviral Therapy for HCV Infection Affecting People Who Inject Drugs Delivered in a Multidisciplinary Setting. |
| Q39326974 | Real-world challenges for hepatitis C virus medications: a critical overview |
| Q90079314 | Real-world effectiveness and safety of sofosbuvir and nonstructural protein 5A inhibitors for chronic hepatitis C genotype 1, 2, 3, 4, or 6: a multicentre cohort study |
| Q38677852 | Real-world effectiveness of sofosbuvir-based treatment regimens for chronic hepatitis C genotype 3 infection: results from the multicenter German hepatitis C cohort (GECCO-03). |
| Q39025575 | Real-world use, effectiveness and safety of anti-viral treatment in chronic hepatitis C genotype 3 infection |
| Q35036061 | Reassessment of genotype 1 hepatitis C virus subtype misclassification by LiPA 2.0: implications for direct-acting antiviral treatment |
| Q26750476 | Recent Advances in Antiviral Therapy for Chronic Hepatitis C |
| Q36575497 | Recent advances in management of the HIV/HCV coinfected patient |
| Q26752433 | Recent advances in managing chronic HCV infection: focus on therapy in patients with severe liver disease |
| Q54223871 | Recent update of the 2017 Korean Association for the Study of the Liver (KASL) treatment guidelines of chronic hepatitis C: comparison of guidelines from other continents, 2017 AASLD/IDSA and 2016 EASL. |
| Q41047662 | Recommendations for the management of hepatitis C virus infection among people who inject drugs |
| Q38229320 | Recurrent HCV after liver transplantation-mechanisms, assessment and therapy |
| Q40064478 | Regional differences in treatment rates for patients with chronic hepatitis C infection: Systematic review and meta-analysis |
| Q50098527 | Resistance analysis of genotype 3 HCV indicates subtypes inherently resistant to NS5A inhibitors. |
| Q34580799 | Resistance patterns associated with HCV NS5A inhibitors provide limited insight into drug binding |
| Q38213847 | Response-guided therapy in patients with genotype 1 hepatitis C virus: current status and future prospects |
| Q36214085 | Retinoid derivative Tp80 exhibits anti-hepatitis C virus activity through restoration of GI-GPx expression. |
| Q38198089 | Review article: genetic factors that modify the outcome of viral hepatitis |
| Q38703524 | Review article: safety and tolerability of direct-acting anti-viral agents in the new era of hepatitis C therapy |
| Q38503778 | Review article: the efficacy and safety of daclatasvir in the treatment of chronic hepatitis C virus infection |
| Q50262230 | Revisiting policy on chronic HCV treatment under the Thai Universal Health Coverage: An economic evaluation and budget impact analysis. |
| Q38355069 | Revolution in hepatitis C antiviral therapy |
| Q59049605 | Ribavirin at the Era of Novel Direct Antiviral Agents for the Treatment of Hepatitis C Virus Infection: Relevance of Pharmacological Monitoring |
| Q37563692 | Ribavirin revisited in the era of direct-acting antiviral therapy for hepatitis C virus infection |
| Q40053677 | Ribavirin steady-state plasma level is a predictor of sustained virological response in hepatitis C-infected patients treated with direct-acting antivirals. |
| Q42216666 | Ribavirin with interferon for hepatitis C in dialysis patients: efficacious and safe in the right patients in good hands |
| Q42682838 | Ribavirin-free treatment may soon be a reality |
| Q40787997 | Ritonavir-boosted danoprevir-based regimens in treatment-naive and prior null responders with HCV genotype 1 or 4 and compensated cirrhosis |
| Q38407722 | Ritonavir-boosted protease inhibitor based therapy: a new strategy in chronic hepatitis C therapy |
| Q35779058 | Role of genetic polymorphisms in hepatitis C virus chronic infection |
| Q37216507 | SASLT guidelines: Update in treatment of Hepatitis C virus infection |
| Q37399645 | Safe and effective sofosbuvir-based therapy in patients with mental health disease on hepatitis C virus treatment |
| Q26745769 | Safety and efficacy of daclatasvir in the management of patients with chronic hepatitis C |
| Q64083501 | Safety and efficacy of the combination simeprevir-sofosbuvir in HCV genotype 1- and 4-mono-infected patients from the French ANRS CO22 hepather cohort |
| Q40950331 | Safety and tolerability of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic hepatitis C virus genotype 1 infection: Analysis of phase III ION trials |
| Q38818416 | Safety of direct antiviral agents in the management of hepatitis C. |
| Q38903835 | Safety of interferon-free therapies for chronic hepatitis C: a network meta-analysis. |
| Q90016593 | Safety-Engineered Syringes: An Intervention to Decrease Hepatitis C Burden in Developing Countries-A Cost-Effectiveness Analysis From Egypt |
| Q36145716 | Second-generation direct-acting-antiviral hepatitis C virus treatment: Efficacy, safety, and predictors of SVR12. |
| Q89767015 | Sequential Circulating Tumor Cell Counts in Patients with Locally Advanced or Metastatic Hepatocellular Carcinoma: Monitoring the Treatment Response |
| Q36519135 | Short interferon and ribavirin treatment for HCV genotype 2 or 3 infection: NORDynamIC trial and real-life experience |
| Q40413372 | Short-duration treatment for chronic hepatitis C virus with daclatasvir, asunaprevir, beclabuvir and sofosbuvir (FOURward study). |
| Q35491398 | Should NS5A inhibitors serve as the scaffold for all-oral anti-HCV combination therapies? |
| Q40821688 | Simeprevir plus sofosbuvir (12 and 8 weeks) in hepatitis C virus genotype 1-infected patients without cirrhosis: OPTIMIST-1, a phase 3, randomized study |
| Q42202756 | Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study |
| Q38219424 | Sofosbuvir (Sovaldi) for the treatment of hepatitis C. |
| Q54964642 | Sofosbuvir Plus Daclatasvir in Treatment of Chronic Hepatitis C Genotype 4 Infection in a Cohort of Egyptian Patients: An Experiment the Size of Egyptian Village. |
| Q47368128 | Sofosbuvir and daclatasvir therapy in patients with hepatitis C-related advanced decompensated liver disease (MELD ≥ 15). |
| Q42207118 | Sofosbuvir for the treatment of hepatitis C virus infection |
| Q38383410 | Sofosbuvir for treatment of chronic hepatitis C. |
| Q52584071 | Sofosbuvir plus Daclatasvir with or without ribavirin for treatment of chronic HCV genotype 4 patients: real-life experience. |
| Q38954096 | Sofosbuvir plus simeprevir for the treatment of genotype 1 chronic hepatitis C: a review of evidence |
| Q55243551 | Sofosbuvir, a New Nucleotide Analogue, for the Treatment of Chronic Hepatitis C Infection. |
| Q38245128 | Sofosbuvir, a novel nucleotide analogue inhibitor used for the treatment of hepatitis C virus |
| Q60047941 | Sofosbuvir, velpatasvir and voxilaprevir: a new triple combination for hepatitis C virus treatment. One pill fits all? Is it the end of the road? |
| Q92553446 | Sofosbuvir-based regimen for genotype 2 HCV infected patients in Taiwan: A real world experience |
| Q40635393 | Sofosbuvir-based treatment of hepatitis C with severe fibrosis (METAVIR F3/F4) after liver transplantation |
| Q35037688 | Sofosbuvir-based treatment regimens for chronic, genotype 1 hepatitis C virus infection in U.S. incarcerated populations: a cost-effectiveness analysis |
| Q50283110 | Sofosbuvir: A Nucleotide NS5B Inhibitor for the Treatment of Chronic Hepatitis C Infection |
| Q24562950 | Sofosbuvir: a novel oral agent for chronic hepatitis C |
| Q38222679 | Sofosbuvir: a review of its use in patients with chronic hepatitis C. |
| Q35667588 | Successes and Challenges on the Road to Cure Hepatitis C |
| Q58579066 | Successful Treatment of Fibrosing Cholestatic Hepatitis With Daclatasvir and Asunaprevir After Liver Transplantation: A Case Report |
| Q55027157 | Successful direct acting antiviral (DAA) treatment of HCV/HIV-coinfected patients before and after liver transplantation. |
| Q42164795 | Sustained virologic response achieved after curative treatment of hepatitis C virus-related hepatocellular carcinoma as an independent prognostic factor |
| Q41673507 | Sustained virological response to antiviral therapy improves survival rate in patients with recurrent hepatitis C virus infection after liver transplantation |
| Q26768128 | Systematic Review and Network Meta-Analysis of Randomized Controlled Trials: Comparative Effectiveness and Safety of Direct-Acting Antiviral Agents for Treatment-Naive Hepatitis C Genotype 1 |
| Q56924599 | Systematic overview of hepatitis C infection in the Middle East and North Africa |
| Q34522481 | Systematic review: current concepts and challenges for the direct-acting antiviral era in hepatitis C cirrhosis |
| Q42061089 | T-cell immunity and hepatitis C virus reinfection after cure of chronic hepatitis C with an interferon-free antiviral regimen in a chimpanzee |
| Q57946696 | Tackling HCV-3 in Asia: Breakthroughs for Efficient and Cost-effective Treatment Strategies |
| Q38796348 | Targeting the Channel Activity of Viroporins. |
| Q36109002 | Temporal dynamics of inflammatory cytokines/chemokines during sofosbuvir and ribavirin therapy for genotype 2 and 3 hepatitis C infection |
| Q37555313 | The HCV Treatment Revolution Continues: Resistance Considerations, Pangenotypic Efficacy, and Advances in Challenging Populations |
| Q37084628 | The HCV care continuum among people who use drugs: protocol for a systematic review and meta-analysis |
| Q36446133 | The Impact of Enhanced Screening and Treatment on Hepatitis C in the United States |
| Q35849638 | The Impact of PNPLA3 rs738409 SNP on Liver Fibrosis Progression, Portal Hypertension and Hepatic Steatosis in HIV/HCV Coinfection |
| Q26777716 | The New Era of Interferon-Free Treatment of Chronic Hepatitis C |
| Q35843443 | The Polymerase Chain Reaction: Essential for the Development of Curative Therapy for Hepatitis C |
| Q45347684 | The antigenic variability of HCV in viral HLA-Ag binding is related to the activation of the host immune response |
| Q28602408 | The broad assessment of HCV genotypes 1 and 3 antigenic targets reveals limited cross-reactivity with implications for vaccine design |
| Q45340671 | The changing landscape of adverse drug events associated with chronic hepatitis C virus therapy. |
| Q40826281 | The combination of daclatasvir and sofosbuvir for curing genotype 2 patients who cannot tolerate ribavirin |
| Q38217350 | The current state and future prospects of chronic hepatitis C virus infection treatment |
| Q64913900 | The dawn of a new era in the treatment of HCV infection: A view from the USA. |
| Q40326326 | The discovery of sofosbuvir: a revolution for therapy of chronic hepatitis C. |
| Q34105079 | The dynamic relationship between innate immune biomarkers and interferon-based treatment effects and outcome in hepatitis C virus infection is altered by telaprevir |
| Q36243096 | The effectiveness of daclatasvir based therapy in European patients with chronic hepatitis C and advanced liver disease |
| Q59330347 | The efficacy of paritaprevir/ritonavir/ombitasvir+dasabuvir and ledipasvir/sofosbuvir is comparable in patients who failed interferon-based treatment with first generation protease inhibitors - a multicenter cohort study |
| Q57127580 | The elevated prevalence of risk factors for chronic liver disease among ageing people with hemophilia and implications for treatment |
| Q40215846 | The frequency of acute kidney injury in patients with chronic hepatitis C virus infection treated with sofosbuvir-based regimens |
| Q39075044 | The future disease burden of hepatitis C virus infection in Sweden and the impact of different treatment strategies |
| Q47569740 | The generation of a simian adenoviral vectored HCV vaccine encoding genetically conserved gene segments to target multiple HCV genotypes |
| Q41493589 | The host HLA-A*02 allele is associated with the response to pegylated interferon and ribavirin in patients with chronic hepatitis C virus infection |
| Q40473486 | The impact of directly acting antivirals on the enzymatic liver function of liver transplant recipients with recurrent hepatitis C. |
| Q40649732 | The increasing burden of potentially preventable liver disease among adult liver transplant recipients: A comparative analysis of liver transplant indication by era in Australia and New Zealand |
| Q43034060 | The multifaceted functions of ribavirin: antiviral, immunomodulator, or both? |
| Q28086947 | The new era of hepatitis C virus therapy |
| Q39034453 | The practical management of chronic hepatitis C infection in Japan - dual therapy of daclatasvir + asunaprevir |
| Q38204657 | The rapid evolution of treatment strategies for hepatitis C. |
| Q40201286 | The risk of early occurrence and recurrence of hepatocellular carcinoma in hepatitis C-infected patients treated with direct-acting antivirals with and without pegylated interferon: A Belgian experience. |
| Q38668968 | The role of HCV proteins on treatment outcomes |
| Q38197441 | The role of chemokines in hepatitis C virus-mediated liver disease |
| Q38634221 | The safety of daclatasvir for the treatment of hepatitis C. |
| Q38476041 | Therapy for hepatitis C genotype 3: moving forward. |
| Q43456125 | Three patients treated with daclatasvir and asunaprevir for recurrent hepatitis C after liver transplantation: Case report |
| Q40278746 | Transplantation of kidneys from hepatitis C-positive donors into hepatitis C virus-infected recipients followed by early initiation of direct acting antiviral therapy: a single-center retrospective study. |
| Q39112237 | Treatment Options in Hepatitis C. |
| Q40364008 | Treatment and primary prevention in people who inject drugs for chronic hepatitis C infection: is elimination possible in a high-prevalence setting? |
| Q40873991 | Treatment intensification with boceprevir in HIV-positive patients with acute HCV-genotype 1 infection at high risk for treatment failure |
| Q36076049 | Treatment of Chronic Hepatitis C in the Aged - Does It Impact Life Expectancy? A Decision Analysis |
| Q39591431 | Treatment of HCV genotype 2 with sofosbuvir and ribavirin results in lower sustained virological response rates in real life than expected from clinical trials |
| Q38581478 | Treatment of HCV in Patients who Failed First-Generation PI Therapy: a Review of Current Literature. |
| Q55218109 | Treatment of Hepatitis C Virus (HCV) Genotype 1 Disease. |
| Q40893681 | Treatment of Hepatitis C in HIV-Infected Patients: Moving Towards an Era of All Oral Regimens |
| Q64064438 | Treatment of chronic HCV infection with DAAs in Rio de Janeiro/Brazil: SVR rates and baseline resistance analyses in NS5A and NS5B genes |
| Q38352572 | Treatment of chronic hepatitis C in patients with HIV/HCV coinfection |
| Q40229215 | Treatment of chronic hepatitis C with direct-acting antivirals in patients with β-thalassaemia major and advanced liver disease. |
| Q26740219 | Treatment of chronic hepatitis C with direct-acting antivirals: The role of resistance |
| Q41437131 | Treatment of hepatitis C |
| Q52808389 | Treatment of hepatitis C genotype 1 infection in Germany: effectiveness and safety of antiviral treatment in a real-world setting. |
| Q26820811 | Treatment of hepatitis C in liver transplant patients: interferon out, direct antiviral combos in |
| Q38460386 | Treatment of hepatitis C in patients with cirrhosis: remaining challenges for direct-acting antiviral therapy |
| Q36519126 | Treatment of hepatitis C virus infection for adults and children: Updated Swedish consensus recommendations. |
| Q41934079 | Treatment of hepatitis C virus infection with direct-acting antiviral drugs is safe and effective in patients with hemoglobinopathies. |
| Q40292229 | Treatment of hepatitis C virus infection: updated Swedish Guidelines 2016. |
| Q41624184 | Treatment of hepatitis C: what is known? |
| Q91656453 | Treatment options of patients with chronic hepatitis C who have failed prior therapy |
| Q40448499 | Treatment with daclatasvir and sofosbuvir for 24 weeks without ribavirin in cirrhotic patients who failed first-generation protease inhibitors. |
| Q38705509 | Tumor Necrosis Factor Inhibits Spread of Hepatitis C Virus Among Liver Cells, Independent From Interferons |
| Q40604753 | Twelve-week ribavirin-free direct-acting antivirals for treatment-experienced Chinese with HCV genotype 1b infection including cirrhotic patients |
| Q41043113 | Two patients treated with simeprevir plus pegylated-interferon and ribavirin triple therapy for recurrent hepatitis C after living donor liver transplantation: case report |
| Q36855565 | Two-Year Follow-Up Analysis of Telaprevir-Based Antiviral Triple Therapy for HCV Recurrence in Genotype 1 Infected Liver Graft Recipients as a First Step towards Modern HCV Therapy |
| Q41703167 | Undetectable HCV-RNA at treatment-week 8 results in high-sustained virological response in HCV G1 treatment-experienced patients with advanced liver disease: the International Italian/Spanish Boceprevir/Peginterferon/Ribavirin Name Patients Program. |
| Q38880996 | Update on Current Evidence for Hepatitis C Therapeutic Options in HCV Mono-infected Patients |
| Q26775809 | Update on hepatitis C: Direct-acting antivirals |
| Q35327376 | Uptake and utilization of directly acting antiviral medications for hepatitis C infection in U.S. veterans |
| Q39049155 | Urgency to treat patients with chronic hepatitis C in Asia |
| Q64892074 | Use of Ribavirin for Hepatitis C Treatment in the Modern Direct-acting Antiviral Era. |
| Q38975165 | Use of direct-acting agents for hepatitis C virus-positive kidney transplant candidates and kidney transplant recipients |
| Q36807370 | Utility of hepatitis C viral load monitoring on direct-acting antiviral therapy |
| Q33423299 | Utility of the low-accelerating-dose regimen in 182 liver recipients with recurrent hepatitis C virus |
| Q40597591 | Value of Sustained Virologic Response in Patients with Hepatitis C as a Function of Time to Progression of End-Stage Liver Disease |
| Q42201598 | Viral entry inhibition: too late for hepatitis C, but promising for other viral infections |
| Q92360165 | Viral hepatitis C treatment shortening - what is the limit? |
| Q51073649 | Viral hepatitis: towards the eradication of HCV and a cure for HBV. |
| Q47561388 | Viral kinetics analysis and virological characterization of treatment failures in patients with chronic hepatitis C treated with sofosbuvir and an NS5A inhibitor |
| Q35592257 | Virological response after 6 week triple-drug regimens for hepatitis C: a proof-of-concept phase 2A cohort study |
| Q34175159 | Visualizing hepatitis C virus infection in humanized mice |
| Q41745947 | What are the management issues for hepatitis C in dialysis patients?: hepatitis C virus infection and its treatment in patients with end-stage renal disease |
| Q38569681 | What does the pharmacological future of treating chronic hepatitis C look like? |
| Q34447905 | Which therapeutic option for hepatitis C virus genotype 1? |
| Q38685566 | Why I do not treat patients for mild disease |
| Q28550101 | Will Sofosbuvir/Ledipasvir (Harvoni) Be Cost-Effective and Affordable for Chinese Patients Infected with Hepatitis C Virus? An Economic Analysis Using Real-World Data |
| Q40007128 | Years of life that could be saved from prevention of hepatocellular carcinoma |
Search more.